<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30207281</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>29</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2468-2942</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>15</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Cancer treatment and research communications</Title>                <ISOAbbreviation>Cancer Treat Res Commun</ISOAbbreviation>            </Journal>            <ArticleTitle>A pilot study evaluating chemotherapy tolerability for breast cancer patients who have received prior treatment and chest radiation for Hodgkin Lymphoma.</ArticleTitle>            <Pagination>                <MedlinePgn>1-6</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S2468-2942(17)30139-9</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ctarc.2018.02.001</ELocationID>            <Abstract>                <AbstractText Label="MICROABSTRACT">Women treated with chest radiation for Hodgkin lymphoma (HL) have significantly higher risk of developing breast cancer, and little is known about how these patients tolerate chemotherapy for breast cancer. This small retrospective study identified 15 patients, noting that these patients tolerate proposed chemotherapy regimens for breast cancer in rates similar to those without prior HL and therapeutic radiation.</AbstractText>                <AbstractText Label="PURPOSE">Women treated for Hodgkin lymphoma (HL) with chest radiation have significantly higher risk of developing breast cancer, and little is known about how these patients tolerate chemotherapy for breast cancer.</AbstractText>                <AbstractText Label="METHODS">Women with breast cancer diagnosed from 1986-2015 after radiation for HL were identified from hospitals and clinics in St. Paul and Minneapolis, Minnesota. Patient, tumor and treatment characteristics, and clinical outcomes were abstracted from medical records and summarized using descriptive statistics. Chemotherapy was defined as tolerated if all scheduled doses and cycles were completed without deviation from the initial plan, with lack of grade 3 or higher toxicity attributable to chemotherapy in categories including blood, cardiac, gastrointestinal, fatigue and pain.</AbstractText>                <AbstractText Label="RESULTS">Forty-two patients with breast cancer and prior radiation for HL were identified, 15 of which received chemotherapy for breast cancer. We noted 75% tolerability of taxane-based and 100% tolerability of anthracycline-based chemotherapy, suggesting that most patients with prior radiation for HL tolerate chemotherapy for breast cancer. A subset of patients (N = 7) in this study were also treated with chemotherapy for HL prior to breast cancer diagnosis, and 86% (6 of 7) also tolerated chemotherapy for breast cancer.</AbstractText>                <AbstractText Label="CONCLUSIONS">Treatment of breast cancer is strongly influenced by prior treatment of HL. Although this study was small and did not meet statistical significance, the data suggest that these patients tolerate proposed chemotherapy regimens for breast cancer in rates similar to those without prior HL and therapeutic radiation. Larger studies comparing specific chemotherapy dosing schedules are needed to address this complicated population.</AbstractText>                <CopyrightInformation>Copyright Â© 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Watson</LastName>                    <ForeName>Allison P</ForeName>                    <Initials>AP</Initials>                    <AffiliationInfo>                        <Affiliation>University of Minnesota; Division of Hematology, Oncology and Transplantation, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, United States. Electronic address: watso562@umn.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Peterson</LastName>                    <ForeName>Bruce</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>University of Minnesota; Division of Hematology, Oncology and Transplantation, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Chung</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>University of Minnesota; Division of Radiation Oncology, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Baxstrom</LastName>                    <ForeName>Kate</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>University of Minnesota; Division of Hematology, Oncology and Transplantation, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Turcotte</LastName>                    <ForeName>Lucie</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>University of Minnesota; Division of Pediatric Hematology and Oncology, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vogel</LastName>                    <ForeName>Rachel</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>University of Minnesota; Division of Obstetrics, Gynecology and Women's Health, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Blaes</LastName>                    <ForeName>Anne</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>University of Minnesota; Division of Hematology, Oncology and Transplantation, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, United States.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>02</Month>                <Day>21</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Cancer Treat Res Commun</MedlineTA>            <NlmUniqueID>101694651</NlmUniqueID>            <ISSNLinking>2468-2942</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">Breast cancer chemotherapy</Keyword>            <Keyword MajorTopicYN="Y">Chemotherapy tolerability</Keyword>            <Keyword MajorTopicYN="Y">Hodgkin lymphoma survivors</Keyword>            <Keyword MajorTopicYN="Y">Secondary breast cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>09</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>01</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>02</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30207281</ArticleId>            <ArticleId IdType="pii">S2468-2942(17)30139-9</ArticleId>            <ArticleId IdType="doi">10.1016/j.ctarc.2018.02.001</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>